Biomea Fusion, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
BMEA$0.55-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| 2026 | 2025 | |
| Operating Activities | ||
| Net loss | $(20,743) | $(50,002) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 66 | 935 |
| Non-cash operating lease expense | — | 1,557 |
| Stock-based compensation expense | 3,169 | 5,742 |
| Change in fair value of warrant liability | (3,538) | (227) |
| Gain on sale of property and equipment | (510) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,003 | 1,614 |
| Other assets | (398) | 615 |
| Accounts payable | 73 | (4,703) |
| Accrued expenses and other current liabilities | (107) | 1,308 |
| Operating lease liabilities | (712) | (1,718) |
| Net cash used in operating activities | (21,697) | (44,879) |
| Investing Activities | ||
| Proceeds from sale of property and equipment | 550 | — |
| Net cash provided by investing activities | 550 | — |
| Financing Activities | ||
| Proceeds from issuances of common stock under at the market equity offering program | — | 5,032 |
| Proceeds from issuance of common stock, common warrants and pre-funded warrants from public offering | — | 37,800 |
| Proceeds from stock option exercise and purchases under the employee stock purchase plan | 159 | 117 |
| Payments of financing costs | — | (125) |
| Net cash provided by financing activities | 159 | 42,824 |
| Net decrease in cash, cash equivalents, and restricted cash | (20,988) | (2,055) |
| Cash, cash equivalents, and restricted cash at the beginning of the period | 56,181 | 58,648 |
| Cash, cash equivalents, and restricted cash at the end of the period | $35,193 | $56,593 |
| Non-cash financing and investing activities: | ||
| Financing costs included in accounts payable and accrued liabilities | $— | $619 |
| Reconciliation of cash and cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $34,824 | $56,224 |
| Restricted cash | 369 | 369 |
| Total cash and cash equivalents, and restricted cash | $35,193 | $56,593 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.